Inscripta adds $30M to series C to speed use of its gene editing tools

Inscripta Inc. (Boulder, Colo.) added an untranched $30 million to its series C round to accelerate development and adoption of its CRISPR gene-editing enzymes and tools.

The company had raised $55.5 million in February from existing investors Mérieux Développement, Paladin Capital, Venrock, Foresite, MLS Capital and NanoDimension, and all six participated in the series C expansion. The additional funds bring Inscripta's series C total to $85.5 million. It declined to disclose whether the expansion is the round's final close (see "Genome Toolbox")...